TM editors' note: This article discusses a nano cap. Such stocks are easily manipulated; do your own careful due diligence.

Thinly traded nano-cap Amedica (AMDA) is a biomaterial company that develops and commercializes silicon nitride for biomedical applications. The stock has been trading with massive volatility lately and we wanted to bring it to your attention because we believe it is setting up for a bounce trade at $1.15 here.

We think it is a buy on a mean reversion, but the science behind the name is rather solid as well. Take a look at the crazy action in the last 5 days:

Source: BAD BEAT Investing

In the last two trading days, this nano-cap stock rocketed on a 32x surge in volume in response to its announcement of positive study data supporting the value proposition of its silicon nitride spinal implants. There are several key studies underway. Data released this week was from the Single Center Retrospective Comparative Study

This was a clinical study comparing silicon nitride spinal implants to allograft spacers in cervical fusion. The results show showed faster and more effective outcomes with silicon nitride.

“While silicon nitride might have been expected to perform better in light of its properties, the surprising finding in our study was how good the outcomes with silicon nitride proved to be. Significantly earlier and more effective bone fusion was observed with silicon nitride than allograft spacers at 3- 6-, and 12-month time points after surgery, all the way to 24 months” –Dr. Micah Smith,  principal investigator.

The completion of a retrospective survey of over 2,000 silicon nitride spinal implants implanted in more than 1,000 patients over the last eight years was also completed. The study was designed to understand clinical outcomes from silicon nitride implants in spine fusion from four different clinics in the US.

“Preliminary data analysis toward publication of this study is very encouraging in this large cohort of patients derived from our long-term surgeon users. Not only are the data consistent with our other clinical studies, but the outcomes corroborate our basic science understanding of the surface chemistry of the material, the key strength of silicon nitride”